Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply

JAMA Oncol. 2020 Apr 1;6(4):590. doi: 10.1001/jamaoncol.2020.0068.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biomarkers
  • DNA Polymerase III / genetics
  • Humans
  • Immune Checkpoint Inhibitors*
  • Immunotherapy
  • Mutation
  • Neoplasms*
  • Treatment Outcome

Substances

  • Biomarkers
  • Immune Checkpoint Inhibitors
  • POLD1 protein, human
  • DNA Polymerase III